Join the Plaque Psoriasis group to help and get support from people like you.
Plaque Psoriasis News
Psoriasis, With or Without Psoriatic Arthritis, Associated With Fatigue
MONDAY, July 1, 2024 – Psoriasis is associated with fatigue, especially among those with psoriatic arthritis (PsA), according to a study published in the July issue of the Journal of the American...
Coexistence of Psoriatic Arthritis, Atopic Dermatitis May Offer Treatment Insights
MONDAY, May 13, 2024 – Psoriatic arthritis (PsA) and atopic dermatitis (AD) can coexist, and the presence of both conditions may mean special attention should be given to selecting optimal...
Tobacco Smoking Reduces the Odds of Psoriasis Improvement
WEDNESDAY, April 24, 2024 – Tobacco smoking is negatively associated with resolution of psoriasis symptoms, according to a study published in the April issue of Tobacco Induced Diseases. Yan Qiang,...
FDA Approves Selarsdi (ustekinumab-aekn), a Biosimilar to Stelara
REYKJAVIK, Iceland & PARSIPPANY, N.J.--(BUSINESS WIRE) April 16, 2024 --Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...
Mouse Study Yields Clues to Why Psoriasis Worsens
MONDAY, March 25, 2024 – Australian researchers say they have identified a gene mutation that causes the skin disease psoriasis. A chronic inflammatory condition, psoriasis causes red, scaly, itchy...
AAD: Bimekizumab Response Durable at Four Years for Moderate-to-Severe Psoriasis
FRIDAY, March 15, 2024 -- Patients with psoriasis treated with bimekizumab rapidly achieve high levels of clinical and health-related quality-of-life responses that are durable at four years, ...
FDA Approves Simlandi (adalimumab-ryvk), an Interchangeable Biosimilar to Humira
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) – Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...
Deep Learning Improves Diagnostic Accuracy for Skin Diseases
FRIDAY, Feb. 16, 2024 – Deep learning-aided decision support improves diagnostic accuracy for skin disease, according to a study published online Feb. 5 in Nature Medicine. Matthew Groh, Ph.D., from...
JNJ-77242113 Shows Greater Efficacy Than Placebo for Plaque Psoriasis
THURSDAY, Feb. 8, 2024 – For patients with moderate-to-severe plaque psoriasis, the interleukin-23-receptor antagonist peptide JNJ-77242113 shows greater efficacy than placebo, according to a study...
Biological Agent Trials for Psoriasis Rarely Include Patient Images
FRIDAY, Dec. 29, 2023 – Few randomized controlled trials involving biological agents for psoriasis treatment include patient images, according to a review published online Nov. 15 in the Journal of...
Skin Conditions Flare Up When Wildfires Nearby
TUESDAY, Dec. 26, 2023 – The smoke billowing from this summer’s devastating wildfires wasn’t just bad for your lungs. Skin problems also seem to worsen, with dermatology visits rising as air quality ...
Skin Diseases Pose a Psychosocial Burden
THURSDAY, Nov. 2, 2023 – Skin diseases can cause a psychosocial burden and feelings of stigmatization, according to a study published online Oct. 8 in the Journal of the European Academy of ...
FDA Approves Wezlana (ustekinumab-auub), an Interchangeable Biosimilar to Stelara
October 31, 2023 – Today, the U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory...
Monthly News Roundup - October 2023
FDA Clears Loqtorzi as First Treatment for Nasopharyngeal Carcinoma (NPC) In October, the U.S. Food and Drug Administration (FDA) approved Coherus BioSciences’ Loqtorzi (toripalimab-tpzi) to treat a...
Tapinarof Cream Safe, Effective for Plaque Psoriasis in Intertriginous Areas
WEDNESDAY, Oct. 25, 2023 – Vtama (tapinarof) cream is efficacious, safe, and well tolerated for the treatment of plaque psoriasis in sensitive intertriginous areas, according to a study presented at...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
methylprednisolone, Humira, Enbrel, Remicade, Otezla, Stelara, Cosentyx, Skyrizi, adalimumab, dexamethasone, etanercept, halobetasol, Taltz